Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Alcohol Use Disorder After Bariatric Surgery
NCT07223983Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in alcohol use disorder (AUD) and obesity (2 arms), sponsored by Yale University. Primary endpoints: Percent weight change at 24 weeks, Mean drinks per calendar day at 24 weeks and 3 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)obesity
Beyond the preview
Go deeper on NCT07223983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223983.